

**ABSTRACT:** Biopharmaceuticals are of increasing importance in the treatment of a variety of diseases. A remaining concern associated with their production is the potential introduction of adventitious agents into their manufacturing process, which may compromise the pathogen safety of a product and potentially cause stock-out situations for important medical supplies. To ensure the safety of biological therapeutics, regulatory guidance requires adventitious agent testing (AAT) of the bulk harvest. AAT is a deliberately promiscuous assay procedure which has been developed to indicate, ideally, the presence of any viral contaminant. One of the most important cell lines used in the production of biopharmaceuticals is Chinese hamster ovary (CHO) cells and while viral infections of CHO cells have occurred, a systematic screen of their virus susceptibility has never been published. We investigated the susceptibility of CHO cells to infection by 14 different viruses, including members of 12 families and representatives of the very species that were implicated in previously reported production cell infections. Based on our results, four different infection outcomes were distinguished, based on the possible combinations of the two factors (i) the induction, or not, of a cytopathic effect and (ii) the ability, or not, to replicate in CHO cells. Our results demonstrate that the current AAT is effective for the detection of viruses which are able to replicate in CHO cells. Due to the restricted virus susceptibility of CHO cells and the routine AAT of bulk harvests, our results provide reassurance for the very high safety margins of CHO cell-derived biopharmaceuticals.

Biotechnol. Bioeng. 2010;106: 598–607.
© 2010 Wiley Periodicals, Inc.

**KEYWORDS:** recombinant products; biopharmaceuticals; virus safety; adventitious agent testing; Chinese hamster ovary (CHO) cells; baby hamster kidney (BHK) cells

---

**Introduction**

Biopharmaceuticals such as growth factors, anti-coagulants, therapeutic enzymes and monoclonal antibodies are of increasing importance for public health care. Many of these proteins were initially isolated from tissues or blood of human or other animal origin and had significant viral safety concerns associated with their use. In the 1980s, the first recombinant medicinal products from mammalian cell cultures have become available (for review see Grillberger et al., 2009) and since then, production of therapeutics in cell lines has become prevalent, with more than 165 biopharmaceuticals now approved world-wide (Walsh, 2006). The use of transformed cell lines for the manufacture of therapeutic proteins greatly reduced the risk of human virus transmission, yet other safety concerns arose with the possibility that adventitious agents might be introduced into the manufacturing process through raw materials or personnel. To assure product safety, several measures are in place to minimize the risk of adventitious agent introduction, such as (i) control of the raw material source, (ii) testing of raw materials and the bulk harvest at appropriate stages during the manufacturing process, to confirm absence of adventitious agents (=adventitious agent testing, AAT) and (iii) implementation of virus-inactivation and removal steps.

Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells). The use of this cell line offers several advantages, such as ease of manipulation and a proven safety profile of products from these cells in humans. In addition, a literature survey might suggest that CHO cells are less permissive to infection by viruses than other cell lines used in the production of recombinant proteins, such as baby hamster kidney (BHK) cells (Table I).
Table 1. Overview of previously reported CHO and BHK cell infections by viruses.

| Virus family | Species | CHO cells | BHK cells |
|--------------|---------|-----------|-----------|
| ss (−) RNA   |         |           |           |
| Bunyaviridae |         |           |           |
| Cache Valley virus | Nims (2006), Potts (2008) | — | — |
| Bunyamwera virus | — | Salanueva et al. (2003) | — |
| Northway encephalitis virus | — | McLean et al. (1978) | — |
| Orthomyxoviridae | Influenza A/B virus | Kumari et al. (2007), Chu and Whittaker (2004) | Govorkova et al. (1999) |
| Arenaviridae | Junin virus | — | Ellenberg et al. (2007) |
| Paramyxoviridae | Parainfluenza virus 1/2/3 | Nishio et al. (2005), Shimokata et al. (1981), De et al. (1991) | — |
| | Simian virus 5 | Potts (2008) | He et al. (2002) |
| | Mumps virus | Wisher (2005), Potts (2008) | McComb and Riesser (1979) |
| | Bovine respiratory syncytial virus | — | — |
| | Sendai virus | — | — |
| | Newcastle disease virus | — | Nishio et al. (2006) |
| | Pneumonia virus of mice | — | Weir et al. (1988) |
| Rhabdoviridae | Vesicular stomatitis virus | Potts (2008) | Connor et al. (2006) |
| | Rabies virus | — | Kallel et al. (2002) |
| ss (+) RNA   |         |           |           |
| Coronaviridae | Bovine coronavirus | Francis (2003) | — |
| | Murine hepatitis virus | — | Matsuyama and Taguchi (2000) |
| Flaviviridae | Yellow fever virus | — | Patkar and Kuhn (2008) |
| | Dengue virus | — | Ng et al. (2007) |
| | West Nile virus | — | Widman et al. (2008), Puig-Basagoiti et al. (2007) |
| | Tick borne encephalitis virus | — | Goto et al. (2003) |
| | St. Louis encephalitis virus | — | McLean et al. (1978) |
| Caliciviridae | Vesivirus 2117 | Oehmig et al. (2003), Genzyme (2009) | — |
| Picornaiviridae | Encephalomyocarditis virus | Potts (2008) | — |
| | Coxsackie virus B-3 | Zautner et al. (2006) | Jia et al. (2008) |
| | Theiler’s mouse encephalitis virus | — | Son et al. (2008), Takano-Maruyama et al. (2006) |
| | Foot and mouth disease virus | — | Vagnozzi et al. (2007), Carrillo et al. (2007), Garcia-Briones et al. (2006) |
| | Bovine enterovirus | — | Smyth et al. (2002) |
| | Porcine enterovirus | — | Knowles et al. (1979) |
| Togaviridae | Semliki Forest virus | Marsh and Bron (1997) | — |
| | Sindbis virus | Potts (2008) | Kiiver et al. (2008), Marsh and Bron (1997) |
| | Rubella virus | — | Malathi et al. (2001) |
| | Japanese encephalitis virus | — | Tsai et al. (2007), Su et al. (2002) |
| | Eastern equine encephalitis virus | — | Petrakova et al. (2005) |
| | Venezuelan equine encephalitis virus | — | Petrakova et al. (2005) |
| Arteriviridae | Porcine reproductive and respiratory syndrome virus | — | Shannakihappa et al. (2007) |
| Retroviridae | Foamy virus | — | Li et al. (2002) |
| Reoviridae | Bluetongue virus | Potts (2008) | De et al. (2005) |
| | Epizootic hemorrhagic disease virus | Rabenau et al. (1993) | Aradaib et al. (1998) |
| | Reovirus 1/2/3 | Nims (2006), Potts (2008) | Gaillard and Joklik (1985) |
| | Avian reovirus | — | Chen et al. (2008), Chulu et al. (2007) |
| | Rotavirus | — | Lopez et al. (2006) |
| ss DNA       |         |           |           |
| Parvoviridae | Mice minute virus | Garnick (1996), Nims (2006) | Zoletto (1985), Nettleton and Rweyemamu (1980) |
| Circoviridae | Porcine circovirus 1 | Misinzo et al. (2006) | — |
| ds RNA       |         |           |           |
| Adenoviridae | Adenovirus | Condon et al. (2003) | Hosel et al. (2003) |
| Poxviridae   | Modified vaccinia virus ‘Ankara’ | Najera et al. (2006) | Silvac et al. (2006) |
| Herpesviridae | Pseudorabies virus | Nixdorf et al. (1999) | Gillet et al. (2006) |
| | Murine gammaherpes 68 | — | Conner et al. (2005) |
| | Herpes simplex virus 1 | — | — |
| Iridoviridae | Frog virus 3 | — | Chinchar et al. (2003) |
Viral contaminations of CHO cell-derived bulk harvests are rare, but have occurred. The contaminating viruses were identified as Mice minute virus (Garnick, 1996; Nims, 2006), Reovirus (Nims, 2006), Cache Valley virus (Nims, 2006), Epizootic hemorrhagic disease virus (Rabenau et al., 1993) and most recently, Vesivirus 2117 (Genzyme, 2009). In all of these reported cases, raw materials used in production were suspected as the source of viral contamination (Garnick, 1998; Rabenau et al., 1993; Onions, 2004). Such contamination events usually result in significant interference with production and can lead to complete facility shut down, with a significant risk for stock-out of important medical supplies.

To ensure the safety of recombinant therapeutics, a demonstration of freedom from adventitious viral agents in biopharmaceuticals has become a regulatory requirement (FDA, 1998). AAT procedures have been developed in a deliberately promiscuous fashion to indicate the presence of, ideally, any viral contaminant and involve a broad virus screen on a variety of cell lines, in which cytopathic effect (CPE), hemadsorption (HAD) and hemagglutination (HA) are assayed. In addition, a more specific assay for Mice minute virus is included, as recommended for monoclonal antibody and vaccine production (FDA, 1997; FDA, 2006), in which, for example, CPE and HA are assayed on a susceptible cell line.

Although CHO cells are one of the main cell line used in the production of recombinant therapeutics (Wurm, 2004), no systematic investigation of their virus susceptibility has to date been published. As this information is necessary to understand the safety margins afforded by AAT, we have tested the virus infectability of CHO cells with different viruses, including representatives or the very species involved in previously reported contaminations. The results obtained from this systematic screen confirm the effective-ness of the current AAT system to detect viruses that can replicate in CHO cells.

**Materials and Methods**

**Cells and Viruses**

**Cells Used for Virus Propagation and Titration**

A549 (human epithelial alveolar, American Type Culture Collection [ATCC] no. CCL-185), A9 (mouse fibroblast, CCL-1.4), BT (bovine turbinate, CRL-1390), HeLa (human cervix epithelial, CCL-2) and PK13 (porcine kidney epithelial, CRL-6489) cells were obtained from the ATCC (Rockville, MD.). Vero (African green monkey kidney epithelial) cells were purchased from the European Collection of Cell Cultures (ECACC, Salisbury, UK), ECACC no. 84113001. ATCC. 324K (human newborn kidney fibroblast) cells came from American BioResearch Incorporated (lot #981021, Pullman, WA.). The same Vero cells used for virus propagation and titration (see above) were also used in AAT.

**Viruses**

Viruses were chosen on the basis of literature reports describing their ability to infect CHO cells (Table I). A list of viruses and the cell lines on which they were propagated and titrated is given in Table II. Where the specific virus reported in literature was not available, model viruses were selected, with special emphasis on viruses which might potentially be introduced into the manufacturing process through personnel, for example, Influenza or Parainfluenza virus (Table II).

**Inoculation and Incubation of CHO Cells With Virus**

CHO cells in 6-well plates were incubated with virus for $2 \times 7 \pm 1$ days, when cell culture supernatant was transferred onto new CHO cells after the first $7 \pm 1$ days of incubation (Fig. 1). Inoculations with virus were done at a multiplicity of infection (MOI) = 1, that is, approx. $10^5$ infectious virus particles per well (with the exception of FPV, for which approx. $10^4$ particles/well were used as no higher titer virus stock was available), for 1 h. The inoculum was removed and the cells washed twice with 2 mL of pre-warmed cell culture medium, to remove any un-adsorbed input virus (Fig. 1). The wells were then refilled with 6 mL of CHO medium (Ham’s F12 medium supplemented with 10% FCS [Gibco, Invitrogen, Lofer, Austria], L-glutamine [2 mM], non-essential amino acids [1×], sodium pyruvate [1 mM] and Gentamycin sulfate [100 μg/ml]) and plates were incubated for $7 \pm 1$ days at 36 °C and 4.5 ± 0.5% CO₂, when the CPE on CHO cells was assessed. Consecutively, 2 mL of CHO cell culture supernatant were transferred onto new 6-well plates seeded with CHO cells, filled to a total volume of 6 mL per well with CHO medium and incubated for a further $7 \pm 1$ days, as before (Fig. 1). The presence of infectious virus was tested by titration at various stages throughout the experiment, on a virus-specific susceptible cell line (Table II) and using a TCID₅₀ assay (see below). Samples for titration were taken from (i) the input inoculum, (ii) the second 2 mL washing step, the CHO cell culture supernatant after incubation for (iii) $7 \pm 1$ days (7d) and for (iv) $2 \times 7 \pm 1$ days (14d), and for (v) the virus inoculum after 14 days of incubation at 36 °C (hold control, done for selected representatives of enveloped and non-enveloped viruses) (Fig. 1). For each virus, this setup was done in duplicate and repeated at least once.

**Infectivity Assays**

Samples that potentially contained infectious virus (see above) were titrated by tissue culture infectious dose 50
(TCID₉₀) assay, that is, eightfold replicates of serial half-log sample dilutions were incubated with cells for 7 days and CPE was assessed microscopically. Virus concentrations were calculated according to the Poisson distribution and expressed as viral load ($\log_{10}$ [TCID₉₀]).

Adventitious Agent Testing (AAT)

When results from the CHO cell inoculation and incubation experiments indicated the presence of a replicating virus without/subtle CPE on CHO cells, the 14d CHO cell

| Virus family  | Virus/abbreviation | Rationale for inclusion in study                                                                 | Strain          | Origin                                    | Cell line* |
|---------------|--------------------|--------------------------------------------------------------------------------------------------|-----------------|-------------------------------------------|------------|
| ss (−) RNA    | Bunyaviridae       | Previous contamination (Nims, 2006); potential contaminant of cell culture components of bovine origin (e.g., FBS) | Original        | ATCC VR-298                               | A549       |
|               | Cache Valley virus (CVV) |                                                                                           |                 |                                           |            |
| Orthomyxoviridae | Influenzavirus A (Fowl plaque virus H7N1, FPV) | Experimental infection reported (Kumari et al., 2007; Chu and Whittaker, 2004); respiratory virus and therefore potential contaminant through manufacturing personnel | A/FPV/ Rostock/45/36 | Federal Institute for Risk Evaluation, Berlin, Germany | Vero       |
| Paramyxoviridae | Parainfluenzavirus 3 (PIV-3) | Experimental infection reported (Potts, 2008); respiratory virus and therefore potential contaminant through manufacturing personnel | SF-4            | ATCC VR-281                               | Vero       |
| Rhabdoviridae  | Vesicular stomatitis virus (VSV) | Experimental infection reported (Potts, 2008)                                               | PM394           | ECACC NCP#401                             | Vero       |
| ss (+) RNA    | Coronaviridae       | Model for Bovine coronavirus, for which experimental infection has been shown (Francis, 2003)     | MHV-JHM         | ATCC VR-765                               | A9         |
|               | Murine hepatitis virus (MHV) |                                                                                           |                 |                                           |            |
| Flaviviridae  | Bovine viral diarrhea virus (BVDV) | Potential contaminant of cell culture components of bovine origin (e.g., FBS) | NADL            | ATCC VR-1422                               | BT         |
| Picornaviridae | Encephalomyocarditis virus (EMCV) | Experimental infection reported (Potts, 2008)                                               | EMC             | ATCC VR-129B                               | Vero       |
|               | Coxsackievirus B3 (CVB3) | Experimental infection reported (Zautner et al., 2006)                                       | Nancy           | ATCC VR-30                                 | Vero       |
| Togaviridae   | Ross River virus (RRV) | Model virus for Semliki Forest (Marsh and Bron, 1997) and Sindbis Virus (Potts, 2008), for which experimental infections were reported | na              | Queensland University of Technology, Australia | Vero       |
| ds RNA        | Reoviridae          | Previous contamination (Wisher, 2005); model for Epizootic hemorrhagic disease virus, for which contamination has been reported (Rabenau et al., 1993) | Dearing         | ATCC VR-824                               | Vero       |
| ss DNA        | Paroviridae         | Contamination of cell culture occurred (Garnick, 1996)                                       | Prototype       | ATCC VR-1346                               | A9         |
|               | Mice minute virus (MMV) |                                                                                           |                 |                                           |            |
|               | Porcine parvovirus (PPV) | Potential contaminant of cell culture components of porcine origin (e.g., Trypsin) | Tennessee      | Biological Research Faculty & Facility #PP951024 | PK13       |
| ds DNA        | Adenoviridae        | Model for Human adenovirus, for which experimental infection of a CHO cell clone was reported (Condon et al., 2003) | Adenoid 75      | ATCC VR-5                                 | HeLa       |
|               | Human adenovirus C, Type 5 (hAdV) |                                                                                           |                 |                                           |            |
| Herpesviridae | Pseudorabies virus, Suid herpes virus 1 (PRV) | Genetically modified CHO cells are permissive (Nixdorf, 1999) | Kaplan          | Fed. Res. Inst. for Viral Dis. of Animals, Tubingen, Germany | Vero       |

na, not applicable.

*Viruses were propagated and titrated on the same cell line.
culture supernatant of the respective virus inoculation was further included in AAT. For this, 0.5 mL of 14d CHO cell culture supernatant was added to each well of 6-well plates containing MRC-5, Vero, CHO or 324K cells and incubated for 1 h. The volume in each well was made up to 6 mL with the respective cell culture medium and plates were incubated for 14 days (MRC-5, Vero and CHO cells) or 21 days (324K cells) at 36 ± 2°C, when the CPE was assessed and hemadsorption (HAD) and hemagglutination (HA) assays done. For HAD, wells with MRC-5, Vero and CHO cells were covered with erythrocyte suspensions of three different species (human, chicken 0.5% [v/v] and guinea pig 1% [v/v]). Separate plates were incubated at +2–8°C and 36 ± 2°C for 30 min, the cell culture supernatant removed and the cells washed twice with PBS before microscopic inspection for hemadsorption. For HA, supernatants of MRC-5, Vero, CHO and 324K cells were diluted with 0.9% [w/v] NaCl solution in twofold steps. Erythrocyte suspensions (human, chicken 0.5% [v/v] and guinea pig 1.0% [v/v]) for MRC-5, Vero and CHO cell supernatants, mouse and guinea pig 1.0% [v/v] for 324K supernatants) were added and separate plates incubated for 35 min at +2–8°C and 36 ± 2°C, before hemagglutination was inspected visually. The described AAT is the routine procedure used for the assessment of recombinant protein bulk harvests from CHO cells.

Results and Discussion

The results obtained from the inoculation and incubation of CHO cells with a panel of viruses showed that four different infection outcomes can be distinguished. This differentiation was based on the possible combinations of the two factors (i) induction, or not, of a CPE on CHO cells and (ii) the ability, or not, of the virus to replicate in CHO cells (i.e., the detection of infectious virus on a susceptible cell line, after incubation on CHO cells).

**Virus Induced a CPE During CHO Cell Culture and Replicated/Persisted in CHO Cells**

After 7 ± 1 days of CHO cell incubation with virus, Human Adenovirus (hAdV), Encephalomyocarditis virus (EMCV), Mice minute virus (MMV) and Reovirus-3 (Reo-3) induced a CPE in CHO cell culture (Fig. 2A, Supplementary Table I). However, the CPE associated with hAdV infection of CHO cells was difficult to assess, as the observed cell changes were subtle and no extensive cell layer destruction occurred. The results obtained from the TCID<sub>50</sub> assays indicated that these viruses were able to replicate in CHO cells, which was shown by the high infectious virus concentrations obtained after the 7 ± 1 days incubation, as well as after the re-inoculation and second 7 ± 1 days incubation (Fig. 2A, Supplementary Table I). Similar to the CPE results obtained for hAdV, no clear replication was observed for this virus: the load of infectious virus particles did not increase significantly between the second wash and the supernatant after 7 and 14 days of incubation but remained stable at a mean of 3.0–3.6 log<sub>10</sub> [TCID<sub>50</sub>] throughout the experiment (Fig. 2A, Supplementary Table I). The hAdV hold control showed that this virus is robust (load of 4.3 log<sub>10</sub> [TCID<sub>50</sub>]) after 14 days at 36 ± 2°C, compared to an input of 5.2 log<sub>10</sub> [TCID<sub>50</sub>]), suggesting that infectivity detected after 14 days of incubation might be due to residual input virus. As the results obtained with hAdV were difficult to interpret, this virus was included in the routine AAT, to determine whether hAdV can unmistakably be detected in a contaminated sample. During AAT, the supernatant of CHO cells that had been inoculated and incubated with hAdV for 14 days was added to CHO, MRC-5, Vero and 324K cells. A clear CPE was observed on these cell lines after 14 days of incubation, with the exception of CHO cells (Table III). This lack of a CPE on CHO cells during AAT is a further indication that hAdV is not able to reproduce on CHO cells efficiently, an observation that has been reported previously (Condon et al., 2003). Nevertheless, an Adenovirus-permissive CHO cell clone has been described (Condon et al., 2003) and contamination of CHO cells by these viruses cannot be ruled out. In addition to the detection of hAdV through the induction of a CPE on various cell lines during AAT, the presence of hAdV was clearly shown by HA, as a positive result was obtained with the supernatant of MRC-5 cells (Table III).

Overall, the results obtained for these viruses clearly show that the presence of EMCV, MMV and Reo-3 can be reliably detected through the induction of a CPE on CHO cells, whereas a contamination with hAdV is clearly shown during routine AAT.

**Virus Induced a CPE During CHO Cell Culture But Did Not Replicate/Replicated Variably in CHO Cells**

Ross River virus (RRV), Fowl plague virus (FPV), Cache Valley virus (CVV) and Vesicular stomatitis virus (VSV) rapidly induced a CPE on CHO cells, which became
apparent the latest after 6 days of incubation. However, no or rather variable virus replication was observed, characterized by the presence of no or very little infectious virus after the first 7\(\pm\)1 days of CHO cell incubation and a subsequent variable replication during the second 7\(\pm\)1 days of incubation, which resulted, for example, in the detection of virus loads of <0.9 and 5.4 log\(_{10}\) [TCID\(_{50}\)] for replicates of the same virus (CVV, Fig. 2B, Supplementary Table I). For the Influenza A virus FPV a clear CPE was already observed during the first few days of incubation, yet infectious virus was not detected on the susceptible cell line throughout the course of the experiment. This might have been due to an ability of FPV to initially replicate in CHO cells, which through the induction of a CPE quickly became self-limiting. Subsequently, the thermosensitive progeny virus was inactivated in the CHO supernatant and therefore no infectivity could be detected after re-inoculation on CHO cells and titration on the susceptible cell line. However, this explanation remains speculative and further studies would be required to investigate this observation in more detail.

For RRV, a viral load of 3.4 log\(_{10}\) [TCID\(_{50}\)] was shown only once (out of four determinations) after re-inoculation.

---

**Table III.** Results of the adventitious agent testing (AAT) in which the culture supernatants of hAdV or PIV-3 infected CHO cells were used as inoculum.

| Test                          | hAdV | PIV-3 |
|-------------------------------|------|-------|
| Cytopathic effect (CPE)       |      |       |
| CHO cells                     | –    | –     |
| MRC-5 cells                   | +    | +     |
| Vero cells                    | +    | +     |
| 324K cells                    | +    | +     |
| Hemadsorption (HAD)           |      |       |
| CHO cells                     | –    | +     |
| MRC-5 cells                   | –    | +     |
| Vero cells                    | –    | +     |
| 324K cells                    | na   | na    |
| Hemagglutination (HA)         |      |       |
| CHO cells                     | –    | –     |
| MRC-5 cells                   | +    | +     |
| Vero cells                    | –    | +     |
| 324K cells                    | –    | +     |

(\(\neg\)) negative result, (\(\neg\)) positive result, (na) not applicable.
and the second 7 ± 1 days incubation (day 14; Fig. 2B, Supplementary Table I). TCID$_{50}$ titrations of CVV showed the presence of small amounts of infectious virus once (out of six determinations, 1.2 log$_{10}$ [TCID$_{50}$]) after 7 ± 1 days of virus incubation on CHO cells and twice (out of six determinations) after re-inoculation and the second 7 ± 1 days incubation (4.2 and 5.4 log$_{10}$ [TCID$_{50}$]; day 14; Fig. 2B, Supplementary Table I). VSV replication in CHO cells was variable and small amounts of infectious virus were detected twice (out of four determinations, 0.9 and 1.4 log$_{10}$ [TCID$_{50}$]) after the first 7 ± 1 days incubation and a significant titer was obtained in all replicates after re-inoculation and the second 7 ± 1 days of incubation (mean of four determinations: 4.5 log$_{10}$ [TCID$_{50}$]; day 14, Fig. 2B, Supplementary Table I). These viruses were all rather thermosensitive, as no infectivity was detected in the hold controls after 14 days of incubation at 36 ± 2°C (Fig. 2B, Supplementary Table I). The rapidly induced CPE on CHO cells indicated that all of these viruses were initially able to infect and destroy CHO cells, yet no or few replication-competent progeny viruses were released into the supernatant. In the case of CVV and more so VSV, the ability to reproduce on CHO cells appeared to improve after the first 7 ± 1 days incubation, possibly indicating an adaption of the virus to growth in CHO cells, as higher titers were detected more consistently in the 14d CHO cell culture supernatant (Fig. 2B, Supplementary Table I).

In summary, the results obtained for RRV, FPV, CVV, and VSV showed that these viruses rapidly induced a CPE in CHO cells and any contamination of the CHO cell fermenter would therefore be detected.

**Virus Did Not Induce a CPE During CHO Cell Culture But Replicated in CHO Cells**

Parainfluenza Virus 3 (PIV-3) was included in the study as previous CHO cell infections with this virus, as well as with other members of the Paramyxoviridae (e.g., Simian virus 5, Mumps virus and Bovine respiratory syncytial virus) had been reported (Potts, 2008; Wisher, 2005). In this study, PIV-3 was the only virus that did not induce a CPE, yet was able to replicate moderately in CHO cell culture (Fig. 2C, Supplementary Table I). The infectivity detected on the susceptible cell line after the first and second 7 ± 1 days incubation was not due to residual virus inoculum, as the virus was completely inactivated after 14 days at 36 ± 2°C (viral load of the hold control <0.1 log$_{10}$ [TCID$_{50}$]). PIV-3 was therefore included in AAT, to evaluate whether a PIV-3 contamination could be detected during this routine test. During AAT, the supernatant of CHO cells that had been inoculated and incubated with PIV-3 for 14 days was added to CHO, MRC-5, Vero and 324K cells. A clear CPE was observed on these cell lines after 14 days of incubation, with the exception of CHO cells (Table III). In addition, the presence of PIV-3 was clearly shown with HAD (positive result on CHO, MRC-5 and Vero cells) and with HA (positive result by using MRC-5, Vero and 324K cell culture supernatants) assays (Table III).

Overall, the results indicate that Parainfluenza virus contamination of a manufacturing process would be detected by AAT and the effectiveness of the current AAT system to detect an example of a virus that can replicate in CHO cells without an apparent CPE was confirmed.

**Virus Did Not Induce a CPE During CHO Cell Culture and Did Not Replicate in CHO Cells**

Bovine viral diarrhea virus (BVDV), Coxsackievirus B3 (CVB3), Murine hepatitis virus (MHV), Pseudorabies virus (PRV) and Porcine parvovirus (PPV) did not induce a CPE in CHO cell culture (Fig. 2D, Supplementary Table I). The results obtained from the TCID$_{50}$ assays indicated that these viruses were not able to replicate in CHO cells. No infectious virus was detected throughout the experiment for BVDV, CVB3, and MHV. In the case of PRV and PPV, some residual infectivity was detected after the first 7 ± 1 days incubation (mean of four replicates: 1.3 and 2.0 log$_{10}$ [TCID$_{50}$], respectively), which was reduced to no detectable infectivity after the second 7 ± 1 days incubation for PRV and to 1.1 log$_{10}$ [TCID$_{50}$] for PPV (Fig. 2D, Supplementary Table I). This remaining infectivity was most likely due to the robustness of the viruses, as, for example, the viral load of the PPV hold control was 2.2 log$_{10}$ [TCID$_{50}$] after 14 days at 36 ± 2°C, compared to a virus input of 5.0 log$_{10}$ [TCID$_{50}$].

In summary, none of these viruses were able to infect CHO cells and a potential infection of the cell line would therefore not result in virus replication.

Based on published studies and evidence reported at conferences, a comparison of the virus susceptibility of CHO and BHK cell lines indicated that BHK cells are permissive for a broader range of viruses than CHO cells (Table I). For CHO cells, despite their wide use in various biotechnology applications, only a few documented historical contaminations have occurred (Garnick, 1996; Nims, 2006; Rabenau et al., 1993), which strengthens the argument of inherently high safety margins associated with the use of this cell line.

The current study sought to investigate the effectiveness of AAT, through a systematic evaluation of the CHO cell virus susceptibility and included representatives or the very species of viruses that were involved in previously reported infections: MMV, Reo-3 (also as a model for EHDV) and CVV (Garnick, 1996; Nims, 2006; Rabenau et al., 1993), as well as viruses that might be introduced into the manufacturing process as contaminants of raw materials: PPV, PRV, VSV, MHV, BVDV, EMCV, and RRV (as a model for Semliki forest virus) or that might be transmitted by manufacturing personnel: FPV (as a model for Influenzavirus A), PIV-3, hADV and CVB3. Although experimental infection of CHO cells with Porcine circovirus, a member of the Circoviridae, has been shown (Misinzo et al., 2006), this virus was not included in the present screen, as the previously published experiments showed no
productive replication in CHO cells and no substantial safety concerns are therefore expected from this virus. For Vesivirus 2117, a member of the Caliciviridae and the virus that was implicated in the most recent widely visible cell culture contamination (Genzyme, 2009), a clearly visible CPE on CHO cells had previously been described (Oehmig, et al., 2003) and the virus is therefore detectable during manufacture and AAT. However, this recent contamination of a manufacturing facility painfully underlines that a remaining risk of such events still exists.

In conclusion, our results demonstrate that viral infections of CHO cells are detectable, either through the induction of a clearly visible CPE, or during routine AAT and we provide evidence that the current AAT system is effective for the detection of viruses that can replicate in CHO cells. Our systematic screen gives evidence for the restricted virus susceptibility of CHO cells (as compared to, e.g., BHK cells), which, in combination with an effective routine AAT of bulk harvests, provides high safety margins for CHO-cell derived biopharmaceuticals.

We thank Barbara Potts for raising our interest in the subject and for initial discussions. Noel Barrett and Donald A. Baker are acknowledged for their unconditional and long-standing support of research into the safety of biological products. The contributions of the entire Baxter-BioScience Global Pathogen Safety team, most notably Angelika Anthofer (conduct of experiments), Karin Berka, Bettina York, Claudia Schwarz and Elisabeth Pinter (cell culture and virus propagation), Cecile Klausen, Nicole Schlager, Elisabeth List and Veronika Sulzer (adventitious agent testing), Gerz Szabo and Johannes Geisler (data monitoring and compilation) are herewith gratefully acknowledged.

References

Aradaib IE, Wilson WC, Schore CE, Mohammed ME, Yilma TD, Cullor JS, Osburn BI. 1998. PCR detection of North American and Central African isolates of epizootic hemorrhagic disease virus (EHDV) based on genome segment 10 of EHDV serotype 1. J Clin Microbiol 36:2604–2608.

Carrillo C, Lu Z, Borca MV, Vagnozzi A, Kutish GF, Rock DL. 2007. Genetic and phenotypic variation of foot-and-mouth disease virus during serial passages in a natural host. J Virol 81:13141–13151.

Chen YT, Lin CH, Ji WT, Li SK, Liu HJ. 2008. Proteasome inhibition reduces avian reovirus replication and apoptosis induction in cultured cells. J Virol Methods 151:95–100.

Chinchgar VH, Bryan L, Wang J, Long S, Chinchgar GD. 2003. Induction of apoptosis in frog virus 3-infected cells. Virology 306:303–312.

Chu VC, Whitaker GR. 2004. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc Natl Acad Sci USA 101:18155–18158.

Chulu JL, Lee JH, Lee YC, Liao SH, Lin FL, Shih WL, Liu HJ. 2007. Apoptosis induction by avian reovirus through p33 and mitochondria-mediated pathway. Biochem Biophys Res Commun 356:529–535.

Conner J, Rixon FJ, Brown SM. 2005. Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in Vero cells. J Virol 79:9970–9981.

Connor JH, McKenzie MO, Lyles DS. 2006. Role of residues 121 to 124 of vesicular stomatitis virus matrix protein in virus assembly and virus-host interaction. J Virol 80:3701–3711.

De BP, Lesoon A, Banerjee AK. 1991. Human parainfluenza virus type 3 transcription in vitro: Role of cellular actin in mRNA synthesis. J Virol 65:3268–3275.

De LG, Scavia G, Lorenzetti R, Scaramozzino P, Amaddeo D, Cardeti G, Siciluna M, Ferrari G, Autorino GL. 2005. Identification of Caliciviridae of virus Coxsackie B3 (Diptera: Ceratopogonidae) as a vector of bluetongue virus in central Italy. Vet Rec 156:301–304.

Ellenberg P, Lénoir EN, Scalzo LA. 2007. Superinfection exclusion in BHK-21 cells persistently infected with Junin virus. J Gen Virol 88:2730–2739.

FDA. 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use; available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf (last accessed January 21, 2010).

FDA. 1998. Guidance for industry: QSA viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073454.pdf (last accessed January 21, 2010).

FDA. 2006. Guidance for industry: Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases; available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092122.pdf (last accessed January 21, 2010).

Francis MJ. 2003. Propagation of bovine coronavirus in Chinese hamster ovary cells. United States Patent 6514502: Schering-Plough Veterinary Corporation.

Galliard RK, Joklik WK. 1985. The relative translation efficiencies of reovirus messenger RNAs. Virology 147:336–348.

Garcia-Briones M, Rosas MF, Gonzalez-Magaldi M, Martin-Acebes MA, Sobrino F, Armas-Portela R. 2006. Differential distribution of non-structural proteins of foot-and-mouth disease virus in BHK-21 cells. Virology 349:409–421.

Garnick RL. 1996. Experience with viral contamination in cell culture. Dev Biol Stand 88:49–56.

Garnick RL. 1998. Raw materials as a source of contamination in large-scale cell culture. Dev Biol Stand 93:21–29.

Genzyme. 2009. Genzyme temporarily interrupts production at Allston plant. Press release, June 16, 2009; available at http://www.genzyme.com/corp/media/GENZ%20PR-061609.asp (last accessed January 21, 2010).

Gillet L, Gill MB, Colaco S, Smith CM, Stevenson PG. 2006. Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice. J Gen Virol 87:3515–3527.

Gorochakov R, Frolova E, Sawicki S, Ataseva S, Sawicki D, Frolov I. 2008. A new role for ns polypeptide cleavage in Sindbis virus replication. J Virol 82:6218–6231.

Goto A, Hayakawa D, Yoshii K, Mizutani T, Kariwa H, Takashima I. 2003. A BHK-21 cell culture-adapted tick-borne encephalitis virus mutant is attenuated for neuroinvasiveness. Vaccine 21:4043–4051.

Govorkova EA, Matrosovich MN, Tuzikov AB, Bovin NV, Gerdil C, Fanget B, Webster RG. 1999. Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology 262:31–38.

Grillberger L, Kreil TR, Nasr S, Reiter M. 2009. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 4:186–201.

He B, Paterson RG, Stock N, Durbin JE, Durbin RK, Goodbourn S, Randall RE, Lamb RA. 2002. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: The multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 303:15–32.
Hösel M, Webb D, Schröer J, Doerfler W. 2003. The abortive infection of Syrian hamster cells with human adenovirus type 12. Curr Top Microbiol Immunol 272:415–440.

Jia H, Ge X, Guo X, Yang H, Yu K, Chen Z, Chen Y, Cha Z. 2008. Specific small interfering RNAs-mediated inhibition of replication of porcine encephalomyocarditis virus in BHK-21 cells. Antiviral Res 79:95–104.

Kalleh H, Jouini A, Majoul S, Sourou S. 2002. Evaluation of various serum and animal protein free media for the production of a conventional rabies vaccine in BHK-21 cells. J Biotechnol 95:195–204.

Küver K, Merits A, Sarand I. 2008. Novel vectors expressing anti-apoptotic protein Bcl-2 to study cell death in Semliki Forest virus-infected cells. Virus Res 131:54–64.

Knowles NJ, Buckley LS, Pereira HG. 1979. Classification of porcine enteroviruses by antigenic analysis and cytopathic effects in tissue culture: Description of 3 new serotypes. Arch Virol 62:201–208.

Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM. 2007. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J 4:142.

Li Z, Yang P, Liu H, Li WX. 2002. A new indicator cell line to monitor human foamy virus infection and stability in vitro. Intervirology 45:79–84.

Lopez T, Lopez S, Arias CF. 2006. Heat shock enhances the susceptibility of BHK cells to rotavirus infection through the facilitation of entry and post-entry virus replication steps. Virus Res 121:74–83.

Malathi J, Therese KL, Madhavan HN. 2001. The association of rubella virus in congenital cataract - a hospital-based study in India. J Clin Virol 23:25–29.

Marsh M, Bron R. 1997. SFV infection in CHO cells: Cell-type specific restrictions to productive virus entry at the cell surface. J Cell Sci 110:95–103.

Matsuyama S, Taguchi F. 2000. Impaired entry of soluble receptor-resistant mutants of mouse hepatitis virus into cells expressing MVHR2 receptor. Virology 273:80–89.

McCaman JR, Riesser VW. 1979. Effects of ribavirin on BHK-21 cells acutely or persistently infected with mumps virus. Antimicrob Agents Chemother 15:356–359.

McLean DM, Grass PN, Judd BD, Stolz J, Wong KK. 1978. Transmission of Northway and St. Louis encephalitis viruses by arctic mosquitoes. Arch Virol 57:315–322.

Misínno G, Delputte PL, Meerts P, Lefebvre DJ, Nauwynck HJ. 2006. Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells. J Virol 80:3487–3494.

Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM, Esteban M. 2006. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80:6033–6047.

Neltteton PF, Rweyemamu MM. 1980. The association of alfalfa cress with the contamination of BHK21 clone 13 suspension cells by a parovirus serologically related to the minute virus of mice (MVM). Arch Virol 64:359–374.

Ng CY, Gu F, Phong WY, Chen YL, Lim SP, Davidson A, Vasudevan SG. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. J Virol 81:1368–1381.

Son KN, Becker RP, Kallio P, Lipton HL. 2008. Theiler’s virus-induced intrinsic apoptosis in M1-D macrophages is Bax mediated and restricts virus infectivity: A mechanism for persistence of a cytolytic virus. J Virol 82:4502–4510.

Su HL, Liao CL, Lin YL. 2002. Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. J Virol 76:4162–4171.

Takano-Maruyama M, Osha K, Asakura K, Okuda T. 2009. Theiler’s murine encephalomyelitis virus leader protein amino acid residue 57 regulates subgroup-specific virus growth on BHK-21 cells. J Virol 83:12025–12031.

Vagnozzi A, Stein DA, Iversen PL, Rieder E. 2007. Inhibition of foot-and-mouth disease virus infections in cell cultures with antisense morpholino oligomers. J Virol 81:11699–11680.

Walsh G. 2006. Biopharmaceutical benchmarks. Nature Biotech 24:769–776.

Weir EC, Brownstein DG, Smith AL, Johnson EA. 1988. Respiratory disease and wasting in athymic mice infected with pneumonia virus of mice. Lab Anim Sci 38:133–137.

Widman D, Ishikawa T, Fayzulin R, Bourne N, Mason PW. 2008. Construction and characterization of a second-generation pseudoinfectious
West Nile virus vaccine propagated using a new cultivation system. Vaccine 26:2762–2771.

Wisher M. 2005. BioReliance: From cell line to product – current concepts in biologics safety testing; pre-clinical safety testing of biopharmaceutical products - latest regulatory and technical considerations. Presentation; available at http://cgi.iweb.nuri.net/cgibank/data/board/swsciens/library/The%20Rationale%20for%20Cell%20Line%20Characterisation.pdf (last accessed January 21, 2010).

Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotech 22:1393–1398.

Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M. 2006. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol 80:6629–6636.

Zoletto R. 1985. Parvovirus serologically related to the minute virus of mice (MVM) as contaminant of BHK 21 cl. 13 suspension cells. Dev Biol Stand 60:179–183.